Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
Press releases published on April 1, 2025
Avadel Pharmaceuticals to Present at the 24th Annual Needham Healthcare Conference
GlobeNewswire
·
April 1, 2025
DUBLIN, April 01, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the …
Inspire Medical Systems, Inc. to Report First Quarter 2025 Financial Results on May 5, 2025
GlobeNewswire
·
April 1, 2025
MINNEAPOLIS, April 01, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) will release financial results for the first quarter 2025 after the close of trading on Monday, May 5. Inspire’s management team will host a corresponding …
Merus to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
GlobeNewswire
·
April 1, 2025
UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics …
FeraMAXᴹᴰ est la marque de supplément de fer que les pharmaciens et les médecins au Canada recommandent le plus souvent depuis dix années consécutives
GlobeNewswire
·
April 1, 2025
MISSISSAUGA, Ontario, 01 avr. 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (« BioSyent », titre à la Bourse de croissance TSX : RX) est fière d’annoncer que FeraMAXMD est la marque de supplément de fer la plus recommandée au Canada selon un sondage pancanadien …
FeraMAX® Named #1 Recommended Iron Supplement in Canada by Pharmacists and Physicians for Tenth Consecutive Year
GlobeNewswire
·
April 1, 2025
MISSISSAUGA, Ontario, April 01, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that FeraMAX® is the #1 recommended iron supplement brand in Canada, based on a national survey of Canadian pharmacists and …
Merus nimmt an Kamingespräch auf der 24. jährlichen Needham Virtual Healthcare Conference teil
GlobeNewswire
·
April 1, 2025
UTRECHT, Niederlande, und CAMBRIDGE, Massachusetts, April 01, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), ein Unternehmen für klinische Onkologie, das innovative, multispezifische Antikörper in voller Länge und Antikörper-Wirkstoff-Konjugate ( …
Merus participera à une discussion informelle lors de la 24e conférence annuelle Needham Virtual Healthcare
GlobeNewswire
·
April 1, 2025
UTRECHT, Pays-Bas et CAMBRIDGE, État du Massachussets, 01 avr. 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS), entreprise spécialisée en oncologie développant des anticorps de pleine longueur multispécifiques et des conjugués anticorps-médicament …
Advanced Medical Balloons presents results from HYDRA-PMCF study of hygh-tec®, demonstrating high performance and safety
GlobeNewswire
·
April 1, 2025
HYDRA-PMCF-study evaluated hygh-tec®, a new polyurethane fecal management system hygh-tec® showed a high level of sealing performance (no leakage in 89.3%) and was safe to use (94.2% no signs of infection; GLOBIAD score = 0+1A) Full results will be …
Medera Presented Updated Results from First-In-Human Gene Therapy Trial for Heart Failure with Preserved Ejection Fraction at 2025 HFpEF Summit
GlobeNewswire
·
April 1, 2025
BOSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing a range of next-generation therapeutics, today announced that updated results from its …
Pacira BioSciences to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
GlobeNewswire
·
April 1, 2025
BRISBANE, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will …
Nitrase Therapeutics Presents Preclinical Data from Multiple Studies Demonstrating Its Antibody Prevents Pathological Spread of Parkinson’s Disease in an Oral Presentation at the Alzheimer’s Disease and Parkinson’s Disease (AD/PD) Conference
GlobeNewswire
·
April 1, 2025
- NDC-0524 is a First-in-class Monoclonal Antibody with High Selectivity for Nitrated Alpha-synuclein (nSyn) and is Expected to Begin a Randomized Phase 1/2a Trial in the Fourth Quarter of 2025 - Elevated nSyn is Found in Patients with Parkinson’s Disease, …
Collegium to Participate in 24th Annual Needham Virtual Healthcare Conference
GlobeNewswire
·
April 1, 2025
STOUGHTON, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that management will participate in a fireside chat at the 24th Annual Needham Healthcare Conference being held virtually from April 7-10, …
Avalyn Completes Successful Phase 1 Clinical Trials of AP02, its Novel Inhaled Formulation of Nintedanib, Preparing for Phase 2 Development in Idiopathic Pulmonary Fibrosis
GlobeNewswire
·
April 1, 2025
Topline data from the single- and multiple-ascending dose studies confirmed safety and favorable tolerability profile of AP02 at all dose levels Full safety, tolerability, and pharmacokinetics data to be presented at the American Thoracic Society 2025 …
RESTEM to Participate in Jones Las Vegas Technology and Innovation Conference
GlobeNewswire
·
April 1, 2025
MIAMI, April 01, 2025 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today announced its participation in the Jones Las Vegas …
Lantern Taps Industry Veteran for Labor, Union & Trust
GlobeNewswire
·
April 1, 2025
DALLAS, April 01, 2025 (GLOBE NEWSWIRE) -- Lantern, the Specialty Care Platform connecting 6 million members with the best surgery, cancer and infusions care, has named Lindsay Leeder, MSN, ARNP as Senior Vice President of Labor, Union …
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
April 1, 2025
CHARLESTOWN, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 43,374 restricted …
Scientific Industries to Host Fiscal Year 2024 Financial Results Investor Call on April 1, 2025
GlobeNewswire
·
April 1, 2025
BOHEMIA, N.Y., April 01, 2025 (GLOBE NEWSWIRE) -- Scientific Industries, Inc. (OTCQB: SCND), a life sciences tool provider, and a developer of digitally simplified bioprocessing products, announced it filed the Form 10K and issued a press release on March …
Qualigen seeks to enter the $10 Billion CABG market with non-binding MOU to acquire Marizyme
GlobeNewswire
·
April 1, 2025
CARLSBAD, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced today they have entered a non-binding Memorandum of Understanding (MOU) to acquire Marizyme (OTC: MRZM). Qualigen and Marizyme have …
Sernova Biotherapeutics Provides Update on Phase 1/2 Clinical Trial of Cell Pouch™ Bio-Hybrid Organ for Treatment of Type 1 Diabetes
GlobeNewswire
·
April 1, 2025
DSMB supports advancement for Sernova’s clinical trial Study is on track to meet key clinical trial endpoints LONDON, Ontario and BOSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading …
NeuroNOS Announces Groundbreaking Research Publication by its CSO Demonstrating Mechanism of Action in Alzheimer’s Disease and Reinforcing Platform’s Strength Across Neurological Disorders
GlobeNewswire
·
April 1, 2025
BOSTON, April 01, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a pioneering biopharmaceutical company developing transformative treatments for complex neurological disorders, including Autism Spectrum Disorder (ASD), brain cancers, and Alzheimer’s disease, and a …